ADVERTISEMENT
Mridula George, MD, Talks Neoadjuvant TALA in gBRCA1/2 Mutation-Positive, Early HER2-Negative Breast Cancer
05/01/2021
Mridula George, MD, Rutgers Cancer Institute of New Jersey, discusses the results following the phase 2 study of neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer, presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement